Real-World Experience With Avacopan in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis

Introduction: Postmarketing data on outcomes of avacopan use in antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) are lacking. Methods: We performed a multicenter retrospective analysis of 92 patients with newly diagnosed or relapsing AAV who received therapy with avacopan....

Celý popis

Podrobná bibliografie

Hlavní autoři:	Reza Zonozi, Faten Aqeel, Dustin Le, Frank B. Cortazar, Jugal Thaker, Maria Jose Zabala Ramirez, Sebastian Eduardo Sattui Cortes, Rose Mary Attieh, Madeline Chung, David H. Bulbin, Aisha Shaikh, Karina Guaman, Julia Ford, Colin Diffie, Ora Gewurz-Singer, Gabriel Sauvage, Anushya Jeyabalan, Abdallah Geara, Isabelle Ayoub, Andrew Bomback, Lara L. Khoury, Jason C. George, Kenar D. Jhaveri, Vimal Kumar Derebail, John L. Niles, Duvuru Geetha
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2024-06-01
Edice:	Kidney International Reports
Témata:	avacopan ANCA-associated vasculitis complement remission kidney recovery
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S246802492401605X
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!